NanoViricides Inc (NYSEMKT:NNVC) shares dipped 6.02% to $1.56 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.96 to $1.34. The company has a market cap of $84.99 at 58.18 million shares outstanding.
NanoViricides Inc is a company that is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. Its nanoviricide technology enables direct attacks at multiple points on a virus particle and also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients within the core of the nanoviricide.
In particular, this nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The company has two pre-clinical drug candidates namely its injectable FluCide for severely ill patients and its HerpeCide skin treatment for oral herpes cold sores. Aside from that, its HerpeCide program is poised to produce additional advanced candidates against ocular herpes and shingles.
Analysts such as Midtown Partners and Chardan Capital have maintained their “buy” rating on NanoViricides Inc stock from last year and 2014. Last month, U.S. Senator Chris Murphy visited the company’s campus in Connecticut and remarked that he is impressed with the company.
I was incredibly impressed by the company and enjoyed hearing from employees during my town hall about how I can best help them and other bioscience entrepreneurs cut through red tape. I know the success of our state’s economy is reliant on innovative companies like NanoViricides that tap into the strengths of our state’s workforce and educational institutions, and I’ll be bringing what I learned from today’s visit back to Congress,” he noted.
Last week, NanoViricides Inc released its Market Product Pipeline Review 2016. More details on this report could be shared during the company’s upcoming presentation in the 18th Annual Rodman & Renshaw Global Investment Conference in New York. The company’s CEO, Eugene Seymour, is expected to provide an overview of NanoViricides Inc business and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
